FDA Should Oversee Clinical Trial Disclosure, New York AG Spitzer Says
Executive Summary
FDA should take the lead in defining rules for clinical trial reporting to eliminate the issue of "publication bias," New York Attorney General Eliot Spitzer said during a recent appearance at the Chautauqua Institution in New York
You may also be interested in...
FDA Credibility Crisis: 1990 Generic Drug Scandal May Be Blueprint For 2005
FDA is heading into 2005 facing the most difficult challenge to its credibility as a regulatory agency since the generic drug scandal at the end of the 1980s
FDA Credibility Crisis: 1990 Generic Drug Scandal May Be Blueprint For 2005
FDA is heading into 2005 facing the most difficult challenge to its credibility as a regulatory agency since the generic drug scandal at the end of the 1980s
Forest Settles With Spitzer; Trial Registry Will Focus On Phase III-IV
Forest Labs' settlement agreement with New York Attorney General Eliot Spitzer requires less disclosure of clinical data than an earlier settlement between Spitzer and GlaxoSmithKline